LTX-401 |
| Catalog No.GC31860 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1398051-86-9
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
LTX-401, an oncolytic amino acid derivative, targets the Golgi apparatus.
LTX-401, an oncolytic amino acid derivative, targets the Golgi apparatus[2]. LTX-401 effectively reduces the viability of several tumor cell lines in vitro, with a similar degree of cytotoxicity against non-malignant cell lines such as HUV-EC-C endothelial cells, HaCat keratinocytes and MRC-5 fibroblasts. LTX-401 displays the highest cytotoxic activity against the human malignant melanoma cell line MDA-MB-435S (13.5 μM), and is least active against the human hepatocellular carcinoma cell line HEPG2 (35.4 μM). For the remaining cell lines, LTX-401 exhibits similar IC50 values, varying slightly within the range of 19-32 μM. No in vitro hemolytic activity against RBCs is observed using the same concentrations required for the induction of cell death in cancer cell lines. A 50% hemolysis is observed using higher concentrations of LTX-401 (400 μg/mL=1087 μM)[1].
The majority (9/11) of the animals demonstrate a complete and lasting tumor regression after intratumoral treatment with LTX-401. Samples are collected from selected animals in the treatment group and control group on days 2 and 7 post-treatment with a single i.t injection. The immunolabelling of tumor tissue with anti-CD3 antibody reveals that a majority of the infiltrating cells are CD3+ T cells, whereas tumors injected with vehicle only exhibit tumors with a viable tumor tissue, with minimal necrosis and few lymphocytes[1].
[1]. Liv-Marie Eike, et al. The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma. PLoS One. 2016; 11(2): e0148980. [2]. Heng Zhou, et al. The oncolytic compound LTX-401 targets the Golgi apparatus. Cell Death Differ. 2018 Jan; 25(1): 227-228.
Cell experiment: | The MTT assay is employed to investigate the in vitro cytotoxicity of LTX-401 against a selection of both cancer and non-malignant cell lines. Pre-cultured cells are seeded at a density between 1x104-1.5x104 cells/well. The cytotoxic activity of LTX-401 against human red blood cells (RBCs) is determined by a hemolytic assay using freshly isolated blood from healthy individuals who gave their signed informed consent. RBCs are resuspended to a 10% hematocrit solution before being incubated for 1 h at 37°C with LTX-401 dissolved in PBS at concentrations ranging from 136-1358 μM (50-500 μg/mL). RBCs with PBS and 1% Triton solution alone serves as a negative and positive control, respectively. After centrifuging the samples at 4,000 rpm for 5 minutes, the absorbance of the supernatant is measured at 405 nm on a spectrophotometric microliter plate reader[1]. |
Animal experiment: | Mice[1]Female C57BL/6 wild-type mice, 5-6 weeks old, are used. All animals are housed in the same room and in cages (containing 2-5 mice) specially designed for mice, with a 12 h/12 h day-night cycle, and allowed ad libitum access to high quality food and water. Animals are weighed weekly and monitored several times per week, and no unexpected deaths are observed. B16F1 cells are harvested, washed in serum-free RPMI and injected intradermally (i.d) into the right side of the abdomen in C57BL/6 mice (7.5x104 B16F1 cells per mouse/50 μL RPMI-1640). Palpable tumors (20-30 mm2) are injected intratumorally (i.t) with either LTX-401 (5 mg/mL) or a vehicle (saline) once per day for three consecutive days. Animals are euthanized according to humane endpoints such as a weight loss of >10%, general physical discomfort or reduced activity, severe tumor necrosis or ulceration, or if the tumor size exceeds 130 mm2. All animals are euthanized using cervical dislocation[1]. |
References: [1]. Liv-Marie Eike, et al. The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma. PLoS One. 2016; 11(2): e0148980. | |
| Cas No. | 1398051-86-9 | SDF | |
| Canonical SMILES | [NH3+]CC(CCCC1=CC=CC=C1)(C(NCC[NH3+])=O)CCCC2=CC=CC=C2 | ||
| Formula | C23H35N3O | M.Wt | 369.54 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7061 mL | 13.5303 mL | 27.0607 mL |
| 5 mM | 0.5412 mL | 2.7061 mL | 5.4121 mL |
| 10 mM | 0.2706 mL | 1.353 mL | 2.7061 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *